
Karen Knudsen, CEO of the Parker Institute for Cancer Immunotherapy, believes the central problem in cancer drug development is not discovery, but a broken “translational middle.” In a wide-ranging interview on The BioCentury Show with BioCentury Washington Editor Steve Usdin, Knudsen discussed the Parker Institute’s focus on accelerating the path from scientific breakthrough to medical impact. As it approaches its tenth anniversary, the institute has deployed about $400 million, catalyzing r...
Podzilla Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.

Ep. 115 - Initiate's Owens on what it takes to be AI-native

Ep. 114 - Roivant’s Matt Gline on commercial launches and the future of the vant model

Ep. 113 - Frank Jiang on Hengrui’s rise and China’s new era of biopharma dealmaking

Ep. 112 - Chris Arendt on rebuilding Takeda for AI
Free AI-powered recaps of The BioCentury Show and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.